The RECOVER I

A multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support

Bartley P. Griffith, Mark B. Anderson, Louis E. Samuels, Walter Pae, Yoshifumi Naka, O. Howard Frazier

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Objectives: Cardiogenic shock after cardiac surgery is accompanied by a high mortality rate. Early institution of hemodynamic support with a versatile, easy to insert left ventricular assist device might help bridge patients to recovery or to the next therapy, and improve the outcomes. Methods: Patients developing cardiogenic shock or low cardiac output syndrome after being weaned off cardiopulmonary bypass were enrolled in a prospective single-arm feasibility study (RECOVER I). The primary safety endpoint was the frequency of major adverse events (death, stroke) at 30 days or discharge, whichever was longer. The primary efficacy endpoint was survival of the patient to implementation of the next therapy, which included recovery at 30 days after device removal and bridge-to-other-therapy. Results: Sixteen patients provided informed consent and were enrolled in the study. Hemodynamics improved immediately after the initiation of mechanical support: cardiac index, 1.65 versus 2.7 L/min/m 2 (P = .0001); mean arterial pressure, 71.4 versus 83.1 mm Hg (P = .01); and pulmonary artery diastolic pressure, 28.0 versus 19.8 mm Hg (P < .0001). The pump provided an average of 4.0 ± 0.6 L/min of flow for an average duration of 3.7 ± 2.9 days (range, 1.7-12.6). The primary safety endpoint occurred in 2 patients (13%; 1 stroke and 1 death). For the primary efficacy endpoint, recovery of the native heart function was obtained in 93% of the patients discharged, with bridge-to-other-therapy in 7%. Survival to 30 days, 3 months, and 1 year was 94%, 81%, and 75%, respectively. Conclusions: The use of the Impella 5.0/left direct device is safe and feasible in patients presenting with postcardiotomy cardiogenic shock. The device was rapidly inserted, enabled early support, and yielded favorable outcomes.

Original languageEnglish (US)
Pages (from-to)548-554
Number of pages7
JournalJournal of Thoracic and Cardiovascular Surgery
Volume145
Issue number2
DOIs
StatePublished - Feb 1 2013

Fingerprint

Multicenter Studies
Prospective Studies
Cardiogenic Shock
Hemodynamics
Stroke
Device Removal
Safety
Low Cardiac Output
Equipment and Supplies
Heart-Assist Devices
Survival
Feasibility Studies
Therapeutics
Informed Consent
Cardiopulmonary Bypass
Pulmonary Artery
Thoracic Surgery
Arterial Pressure
Blood Pressure
Mortality

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Griffith, Bartley P. ; Anderson, Mark B. ; Samuels, Louis E. ; Pae, Walter ; Naka, Yoshifumi ; Frazier, O. Howard. / The RECOVER I : A multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. In: Journal of Thoracic and Cardiovascular Surgery. 2013 ; Vol. 145, No. 2. pp. 548-554.
@article{5ff83e5113ca4eae9acc6627a0240615,
title = "The RECOVER I: A multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support",
abstract = "Objectives: Cardiogenic shock after cardiac surgery is accompanied by a high mortality rate. Early institution of hemodynamic support with a versatile, easy to insert left ventricular assist device might help bridge patients to recovery or to the next therapy, and improve the outcomes. Methods: Patients developing cardiogenic shock or low cardiac output syndrome after being weaned off cardiopulmonary bypass were enrolled in a prospective single-arm feasibility study (RECOVER I). The primary safety endpoint was the frequency of major adverse events (death, stroke) at 30 days or discharge, whichever was longer. The primary efficacy endpoint was survival of the patient to implementation of the next therapy, which included recovery at 30 days after device removal and bridge-to-other-therapy. Results: Sixteen patients provided informed consent and were enrolled in the study. Hemodynamics improved immediately after the initiation of mechanical support: cardiac index, 1.65 versus 2.7 L/min/m 2 (P = .0001); mean arterial pressure, 71.4 versus 83.1 mm Hg (P = .01); and pulmonary artery diastolic pressure, 28.0 versus 19.8 mm Hg (P < .0001). The pump provided an average of 4.0 ± 0.6 L/min of flow for an average duration of 3.7 ± 2.9 days (range, 1.7-12.6). The primary safety endpoint occurred in 2 patients (13{\%}; 1 stroke and 1 death). For the primary efficacy endpoint, recovery of the native heart function was obtained in 93{\%} of the patients discharged, with bridge-to-other-therapy in 7{\%}. Survival to 30 days, 3 months, and 1 year was 94{\%}, 81{\%}, and 75{\%}, respectively. Conclusions: The use of the Impella 5.0/left direct device is safe and feasible in patients presenting with postcardiotomy cardiogenic shock. The device was rapidly inserted, enabled early support, and yielded favorable outcomes.",
author = "Griffith, {Bartley P.} and Anderson, {Mark B.} and Samuels, {Louis E.} and Walter Pae and Yoshifumi Naka and Frazier, {O. Howard}",
year = "2013",
month = "2",
day = "1",
doi = "10.1016/j.jtcvs.2012.01.067",
language = "English (US)",
volume = "145",
pages = "548--554",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "2",

}

The RECOVER I : A multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support. / Griffith, Bartley P.; Anderson, Mark B.; Samuels, Louis E.; Pae, Walter; Naka, Yoshifumi; Frazier, O. Howard.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 145, No. 2, 01.02.2013, p. 548-554.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The RECOVER I

T2 - A multicenter prospective study of Impella 5.0/LD for postcardiotomy circulatory support

AU - Griffith, Bartley P.

AU - Anderson, Mark B.

AU - Samuels, Louis E.

AU - Pae, Walter

AU - Naka, Yoshifumi

AU - Frazier, O. Howard

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Objectives: Cardiogenic shock after cardiac surgery is accompanied by a high mortality rate. Early institution of hemodynamic support with a versatile, easy to insert left ventricular assist device might help bridge patients to recovery or to the next therapy, and improve the outcomes. Methods: Patients developing cardiogenic shock or low cardiac output syndrome after being weaned off cardiopulmonary bypass were enrolled in a prospective single-arm feasibility study (RECOVER I). The primary safety endpoint was the frequency of major adverse events (death, stroke) at 30 days or discharge, whichever was longer. The primary efficacy endpoint was survival of the patient to implementation of the next therapy, which included recovery at 30 days after device removal and bridge-to-other-therapy. Results: Sixteen patients provided informed consent and were enrolled in the study. Hemodynamics improved immediately after the initiation of mechanical support: cardiac index, 1.65 versus 2.7 L/min/m 2 (P = .0001); mean arterial pressure, 71.4 versus 83.1 mm Hg (P = .01); and pulmonary artery diastolic pressure, 28.0 versus 19.8 mm Hg (P < .0001). The pump provided an average of 4.0 ± 0.6 L/min of flow for an average duration of 3.7 ± 2.9 days (range, 1.7-12.6). The primary safety endpoint occurred in 2 patients (13%; 1 stroke and 1 death). For the primary efficacy endpoint, recovery of the native heart function was obtained in 93% of the patients discharged, with bridge-to-other-therapy in 7%. Survival to 30 days, 3 months, and 1 year was 94%, 81%, and 75%, respectively. Conclusions: The use of the Impella 5.0/left direct device is safe and feasible in patients presenting with postcardiotomy cardiogenic shock. The device was rapidly inserted, enabled early support, and yielded favorable outcomes.

AB - Objectives: Cardiogenic shock after cardiac surgery is accompanied by a high mortality rate. Early institution of hemodynamic support with a versatile, easy to insert left ventricular assist device might help bridge patients to recovery or to the next therapy, and improve the outcomes. Methods: Patients developing cardiogenic shock or low cardiac output syndrome after being weaned off cardiopulmonary bypass were enrolled in a prospective single-arm feasibility study (RECOVER I). The primary safety endpoint was the frequency of major adverse events (death, stroke) at 30 days or discharge, whichever was longer. The primary efficacy endpoint was survival of the patient to implementation of the next therapy, which included recovery at 30 days after device removal and bridge-to-other-therapy. Results: Sixteen patients provided informed consent and were enrolled in the study. Hemodynamics improved immediately after the initiation of mechanical support: cardiac index, 1.65 versus 2.7 L/min/m 2 (P = .0001); mean arterial pressure, 71.4 versus 83.1 mm Hg (P = .01); and pulmonary artery diastolic pressure, 28.0 versus 19.8 mm Hg (P < .0001). The pump provided an average of 4.0 ± 0.6 L/min of flow for an average duration of 3.7 ± 2.9 days (range, 1.7-12.6). The primary safety endpoint occurred in 2 patients (13%; 1 stroke and 1 death). For the primary efficacy endpoint, recovery of the native heart function was obtained in 93% of the patients discharged, with bridge-to-other-therapy in 7%. Survival to 30 days, 3 months, and 1 year was 94%, 81%, and 75%, respectively. Conclusions: The use of the Impella 5.0/left direct device is safe and feasible in patients presenting with postcardiotomy cardiogenic shock. The device was rapidly inserted, enabled early support, and yielded favorable outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84872327034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872327034&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2012.01.067

DO - 10.1016/j.jtcvs.2012.01.067

M3 - Article

VL - 145

SP - 548

EP - 554

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 2

ER -